Utility of brain FDG-PET in primary CNS lymphoma

Clin Adv Hematol Oncol. 2008 Nov;6(11):818-20, 840.

Abstract

18Fluoro-deoxyglucose positron emission tomography (FDG-PET) imaging has been widely incorporated into the management of systemic non-Hodgkin lymphoma. However, its utility in primary central nervous system lymphoma (PCNSL) is unclear. We report 28 PCNSL patients who underwent brain FDG-PET to inform clinical management. Baseline PET imaging demonstrated hypermetabolism consistent with aggressive lymphoma in 75% (9/12) of patients. FDG-PET used for response assessment or the interpretation of nonspecific magnetic resonance imaging abnormalities showed hypermetabolism in 50% (10/20) of patients, which was important in guiding further management. This data suggests that FDG-PET imaging in PCNSL is useful and may have a role in response assessment.

Publication types

  • Validation Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Brain / pathology
  • Brain Neoplasms / diagnostic imaging*
  • Brain Neoplasms / pathology
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Lymphoma / diagnostic imaging*
  • Lymphoma / pathology
  • Male
  • Middle Aged
  • Positron-Emission Tomography / methods*
  • Radiopharmaceuticals*

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18